Abstracts tagged "Patient reported outcomes"

Abstract Number: 0543 • ACR Convergence 2020
Exercise Among Older Adults Living with Rheumatic Disease: Physical Activity Habits and Patient Reported Outcomes
Alexis Ogdie¹, Sofia Pedro², Joshua Baker³, Kaleb Michaud⁴ and Patricia Katz⁵, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: Among patients with rheumatic disease, physical activity is important for maintaining health and improving outcomes. EULAR recommendations suggest at least 30 min of vigorous…
Abstract Number: 1018 • ACR Convergence 2020
Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)
Lijun Wu¹, Zhanyun Da², Hongzhi Wang³, Jianlin Huang⁴, Bin Wu⁵, Henglian Wu⁶, Fang He⁷, Fen Wang⁸, Rong Du⁹, Linchong Su¹⁰, Qiaoqiao Yao¹¹, Rui Wu¹², Zhenbin Li¹³, Xiaohan Wang¹⁴, Yuhong Liu⁹, Chuanjing Li¹⁵, Xiaomei Lei¹⁶, Minjun Wang¹⁷, Hui Xiao¹⁷, Yuhua Jia¹⁸, Yihong Liu¹⁷, Xin Chen¹⁷, Shengsong Jia¹⁷, Bing Wu¹⁸, Yuan Liu¹⁷, Fei Xiao¹⁸ and Lingli Dong¹⁹, ¹People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ²The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), ³The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁴The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁵Chongqing Hospital of Traditional Chinese Medicine, chongqing, Chongqing, China (People's Republic), ⁶Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ⁷Suining Central Hospital, Suining, Sichuan, China (People's Republic), ⁸The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), ⁹Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁰Minda Hospital of Hubei Minzu University, Enshi, Hubei, China (People's Republic), ¹¹China Resources Wuhan Iron and Steel General Hospital, Wuhan, Hubei, China (People's Republic), ¹²The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹³Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), ¹⁴Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁵Xiaogan Central Hospital of Hubei Province, Xiaogan, Hubei, China (People's Republic), ¹⁶Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁷Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁸Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁹Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic)
Background/Purpose: Treat-to-Target(T2T) is the main therapeutic strategy for patients with RA and SLE. There has been no report on comparation of seasonal variations on T2T…
Abstract Number: 1228 • ACR Convergence 2020
Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
Clifton Bingham III¹, Bochao Jia², Jianmin Wu², Amanda Quebe², Carol Kannowski², Susan Otawa², Yun-Fei Chen², Kirstin Griffing², Dongyi He³ and Dalton Sholter⁴, ¹Johns Hopkins University, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Shanghai Guanghua Hospital, Shanghai, Shanghai, China (People's Republic), ⁴University of Alberta, Edmonton, AB, Canada
Background/Purpose: Baricitinib (BARI) improved patient-reported outcomes (PROs) in patients with insufficient response or intolerance to ≥1 tumor necrosis factor inhibitors (TNFi) or other biological disease-modifying…
Abstract Number: 1371 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
Vibeke Strand¹, Filip Van den Bosch², Roberto Ranza³, Ying Ying Leung⁴, Edit Drescher⁵, Apinya Lertratanakul⁶, Ralph Lippe⁷, Christopher Saffore⁶, Patrick Zueger⁶ and Peter Nash⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Ghent University Hospital, Ghent, Belgium, ³Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Department of Rheumatology & Immunology, Singapore General Hospital, Singapore, Singapore, ⁵Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: The efficacy and safety of upadacitinib (UPA), a selective Janus kinase inhibitor, in patients with PsA is under investigation in Phase 3 clinical trials.…
Abstract Number: 1685 • ACR Convergence 2020
Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe
Jonathan Hausmann¹, Kevin Kennedy², Salman Surangiwala³, Maggie Larche⁴, Karen Durrant⁵, Rashmi Sinha⁶ and Emily Sirotich⁴, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Autoinflammatory Alliance, San Francisco, CA, ⁶SJIA Foundation, Cincinnati
Background/Purpose: Children with rheumatic diseases face unknown risks in the setting of the COVID-19 pandemic. These children are often immunosuppressed due to their underlying disease…
Abstract Number: 1947 • ACR Convergence 2020
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis affecting patients aged above 50 years. Its clinical manifestations such as headache, jaw claudication…
Abstract Number: 0154 • ACR Convergence 2020
Treatment Decision Making Among Axial Spondyloarthritis Patients: Real-World Data from the ArthritisPower Registry
William Nowell¹, Theresa Hunter², Kelly Gavigan³, Jeffrey R Curtis⁴, William Malatestinic⁵, Rebecca Bolce⁵, Jeffrey Lisse⁵, Andris Kronbergs⁵, Carol Himelein⁵, Jennifer Walker⁶ and Jessica Walsh⁷, ¹Global Healthy Living Foundation, New York City, NY, ²Eli Lilly and Company, Indianapolis, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Global Health Living Foundation, New York City, NY, ⁷University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapy has been shown to be effective in the treatment of axial spondyloarthritis (axSpA).1,2 Little is understood about axSpA…
Abstract Number: 0306 • ACR Convergence 2020
Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Taylor Blachley², Kelechi Emeanuru², Sven Richter³, Benoit Guerette³ and Philip Mease⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Amgen Inc., Thousand Oaks, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939).…
Abstract Number: 0546 • ACR Convergence 2020
Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis
Alexis Ogdie¹, Kathleen Bush¹, Michael George¹, Mitesh Patel¹, William Nowell², Kelly Gavigan³, Jeffrey Curtis⁴ and Joshua Baker⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, New York City, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Regular physical activity may have benefits for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but patients with active disease are often reluctant…
Abstract Number: 1081 • ACR Convergence 2020
Patient-reported Outcomes in Early Autoimmune Inflammatory Myopathies
Valérie Leclair¹, Brett Thombs², Mianbo Wang³, Evelyne Vinet⁴, Alexandra Albert⁵ and Marie Hudson⁶, ¹Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ²Department of Psychology, McGill University, Montreal, QC, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada; Department of Medicine, Université Laval, Québec, QC, Canada., Neuville, Canada, ⁶Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Patient-reported outcomes (PROs) are increasingly used in rheumatology. Such outcomes are under-reported in autoimmune inflammatory myopathies (AIM) especially in incident cohorts. The objective of…
Abstract Number: 1232 • ACR Convergence 2020
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
Andrea Rubbert Roth¹, Daniel Furst*², Stefano Fiore³, Amy Praestgaard⁴, Vivian Bykerk⁵, Clifton Bingham III⁶ and Christina Charles-Schoeman⁷, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
Abstract Number: 1416 • ACR Convergence 2020
Effects of the COVID-19 Pandemic on Patients Living with Vasculitis
Shubhasree Banerjee¹, Michael George², Kalen Young³, Shilpa Venkatachalam⁴, Jennifer Gordon⁵, Cristina Burroughs⁶, David Curtis⁷, Marcela Ferrada⁸, Kelly Gavigan⁹, Peter C. Grayson¹⁰, Joyce Kullman¹¹, Jeffrey R Curtis¹², Dianne Shaw³, William Nowell¹³ and Peter Merkel², ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Foundation, Kansas City, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Temple University, Philadelphia, ⁶University of South Florida, Tampa, ⁷Global Healthy Living Foundation, New York City, ⁸Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹Global Healthy Living Foundation, Upper Nyack, NY, ¹⁰Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ¹¹Vasculitis Foundation, Kansas City, MO, ¹²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Global Healthy Living Foundation, New York City, NY
Background/Purpose: The COVID-19 pandemic has the potential to impact how patients with vasculitis interact with health care systems due to concerns about infections. This study…
Abstract Number: 1723 • ACR Convergence 2020
RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data
Yan Zhao¹, Rong Mu², Xiaomei Li³, Hongsheng Sun⁴, Cundong Mi⁵, Guosheng Wang³, Shengqian Xu⁶, Minghua Xu⁷, Haiying Chen⁸, Qingchun Huang⁹, Ling Lei¹⁰, HaiLi Shen¹¹, Hui Xiao¹², Yuhua Jia¹³, Bing Wu¹³, Xin Chen¹², Shengsong Jia¹² and Fei Xiao¹³, ¹Peking Union Medical College hospital, Beijing, Beijing, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³the First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China (People's Republic), ⁴Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China (People's Republic), ⁵The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁶the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), ⁷Affiliated Hospital of Hebei University, Baoding, Hebei, China (People's Republic), ⁸The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic), ⁹Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic), ¹⁰The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ¹¹Second Hospital of Lanzhou University, Lanzhou, Gansu, China (People's Republic), ¹²Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic)
Background/Purpose: Flare, relapse from status of treat-to-target (T2T, DAS28< =3.2), is hard predicted. We try to make it predictable by applying machine learning to a…
Abstract Number: 1979 • ACR Convergence 2020
Participant Engagement and Adherence in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported Outcome Data Among Rheumatoid Arthritis Patients
William Nowell¹, Jeffrey R Curtis², Hong Zhao³, Fenglong Xie³, Laura Stradford⁴, David Curtis⁵, Kelly Gavigan⁴, Jessica Boles⁴, Justin Owensby³, Cassie Clinton², Ilya Lipkovich⁶, Shilpa Venkatachalam⁷, Sandra Nolot⁶ and Virginia Haynes⁶, ¹Global Healthy Living Foundation, New York City, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, New York City, ⁶Eli Lilly & Company, Indianapolis, IN, ⁷Global Healthy Living Foundation, Upper Nyack
Background/Purpose: Characterization of how different types of patient-generated data reflect patients’ experience is needed to guide integration of electronically collected patient-reported outcome (ePRO) measures and…
Abstract Number: 0004 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases: A Study in 15 Arab Countries
Nelly Ziade¹, Lina El Kibbi², Ihsane Hmamouchi³, Nizar Abdulateef⁴, Hussein Halabi⁵, Wafa Hamdi⁶, Fatemah Abutiban⁷, Manal el Rakawi⁸, Mervat Eissa⁹ and Basel Masri¹⁰, ¹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ²Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ³Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ⁴Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ⁵King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁶Department of Rheumatology, Kassab Institute of orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia, Tunis, Tunisia, ⁷Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ⁸Departement of Rheumatology, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, Blida, Algeria, ⁹Rheumatology Department, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Jordan Hospital, Amman, Jordan, Amman, Jordan
Background/Purpose: To evaluate the impact of the Coronavirus Disease 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].